Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients — initial experience

Niwas et al., Advances in Respiratory Medicine, doi:10.5603/ARM.a2020.0139
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Recovery time 29% Improvement Relative Risk Viral clearance -183% HCQ for COVID-19  Niwas et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 29 patients in India Faster recovery with HCQ (p=0.0082) c19hcq.org Niwas et al., Advances in Respiratory .., Nov 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 418 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments.
5,000+ studies for 104 treatments. c19hcq.org
Retrospective 12 hospitalized patients in India treated with CQ and 17 controls, showing faster recovery with treatment. There was no significant difference in viral clearance. The CQ group mean age was 41.3 vs. 47.6 for controls.
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter et al. show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
recovery time, 29.2% lower, relative time 0.71, p = 0.008, treatment mean 6.3 (±2.7) n=12, control mean 8.9 (±2.2) n=17.
risk of no viral clearance, 183.3% higher, RR 2.83, p = 0.55, treatment 2 of 12 (16.7%), control 1 of 17 (5.9%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Niwas et al., 1 Nov 2020, retrospective, India, peer-reviewed, mean age 45.5, 17 authors. Contact: rniwasaiims@gmail.com.
This PaperHCQAll
Clinical Outcome, Viral Response and Safety Profile of Chloroquine in COVID-19 Patients—Initial Experience
Ram Shahul Niwas, Aneesa Shahul S, M K Garg, Vijaya Lakshmi Nag, Pradeep Kumar Bhatia, Naveen Dutt, Nishant Chauhan, Jaykaran Charan, Shahir Asfahan, Praveen Sharma, Pankaj Bhardwaj, Mithu Banerjee, Pawan Garg, Binit Sureka, Gopal Krishna Bohra, Maya Gopalakrishnan, Sanjeev Misra
Advances in Respiratory Medicine, doi:10.5603/arm.a2020.0139
Introduction: Chloroquine and its analogues are currently being investigated for the treatment and post exposure prophylaxis of COVID-19 due to its antiviral activity and immunomodulatory activity. Material and methods: Confirmed symptomatic cases of COVID-19 were included in the study. Patients were supposed to receive chloroquine (CQ) 500 mg twice daily for 7 days. Due to a change in institutional protocol, initial patients received chloroquine and subsequent patients who did not receive chloroquine served as negative controls. Clinical effectiveness was determined in terms of timing of symptom resolution and conversion rate of reverse transcriptase polymerase chain reaction (RT-PCR) on day 14 and day 15 of admission. Results: Twelve COVID-19 patients formed the treatment arm and 17 patients were included in the control arm. The duration of symptoms among the CQ treated group (6.3 ± 2.7 days) was significantly (p-value = 0.009) lower than that of the control group (8.9 ± 2.2 days). There was no significant difference in the rate of RT-PCR negativity in both groups. 2 patients out of 12 developed diarrhea in the CQ therapy arm. Conclusion: The duration of symptoms among the treated group (with chloroquine) was significantly lower than that of the control group. RT-PCR conversion was not significantly different between the 2 groups.
Conflict of interest None declared.
References
Agostini, Andres, Sims, Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease, mBio, doi:10.1128/mBio.00221-18
Gao, Tian, Xu, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Guan, Ni, Yu, Clinical characteristics of coronavirus disease 2019 in china, N Engl J Med, doi:10.1056/NEJMoa2002032
Jie, He, Xi, Zhi, Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumoni-aExpert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia, Chinese
Liu, Xiao, Wei, Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2, J Med Virol, doi:10.1002/jmv.25726
Liu, Zhang, Huang, -novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury
Lu, Zhao, Li, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, doi:10.1016/S0140-6736(20)30251-8
Na, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
Rosendaal, Gautret, Lagier, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Savarino, Ldi, Donatelli, New insights into the antiviral effects of chloroquine, The Lancet Infectious Diseas, doi:10.1016/s1473-3099(06)70361-9
Tang, Cao, Han, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ, doi:10.1136/bmj.m1849
Van Den Broek, Möhlmann, Abeln, Chloroquine-induced QTc prolongation in COVID-19 patients, Neth Heart J, doi:10.1007/s12471-020-01429-7
Wahba, Jain, Fire, A new coronavirus associated with human respiratory disease in China, Nature, doi:10.1038/s41586-020-2008-3
Who, Coronavirus disease (COVID-2019) situation reports
Zumla, Chan, Azhar, Coronaviruses -drug discovery and therapeutic options, Nat Rev Drug Discov, doi:10.1038/nrd.2015.37
{ 'indexed': {'date-parts': [[2022, 4, 2]], 'date-time': '2022-04-02T17:13:32Z', 'timestamp': 1648919612166}, 'reference-count': 0, 'publisher': 'VM Media SP. zo.o VM Group SK', 'issue': '6', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Adv Respir Med'], 'DOI': '10.5603/arm.a2020.0139', 'type': 'journal-article', 'created': {'date-parts': [[2021, 1, 4]], 'date-time': '2021-01-04T12:27:53Z', 'timestamp': 1609763273000}, 'page': '515-519', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': [ 'Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients — ' 'initial experience'], 'prefix': '10.5603', 'volume': '88', 'author': [ {'given': 'Ram', 'family': 'Niwas', 'sequence': 'first', 'affiliation': []}, {'given': 'Aneesa Shahul', 'family': 'S', 'sequence': 'additional', 'affiliation': []}, {'given': 'M K', 'family': 'Garg', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vijaya Lakshmi', 'family': 'Nag', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pradeep Kumar', 'family': 'Bhatia', 'sequence': 'additional', 'affiliation': []}, {'given': 'Naveen', 'family': 'Dutt', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nishant', 'family': 'Chauhan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jaykaran', 'family': 'Charan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shahir', 'family': 'Asfahan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Praveen', 'family': 'Sharma', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pankaj', 'family': 'Bhardwaj', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mithu', 'family': 'Banerjee', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pawan', 'family': 'Garg', 'sequence': 'additional', 'affiliation': []}, {'given': 'Binit', 'family': 'Sureka', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gopal Krishna', 'family': 'Bohra', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maya', 'family': 'Gopalakrishnan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sanjeev', 'family': 'Misra', 'sequence': 'additional', 'affiliation': []}], 'member': '3595', 'published-online': {'date-parts': [[2020, 12, 30]]}, 'container-title': ['Advances in Respiratory Medicine'], 'original-title': [], 'link': [ { 'URL': 'https://journals.viamedica.pl/advances_in_respiratory_medicine/article/viewFile/69692/52404', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 1, 4]], 'date-time': '2021-01-04T12:27:58Z', 'timestamp': 1609763278000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://journals.viamedica.pl/advances_in_respiratory_medicine/article/view/69692'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 12, 30]]}, 'references-count': 0, 'journal-issue': {'issue': '6', 'published-online': {'date-parts': [[2020, 12, 30]]}}, 'URL': 'http://dx.doi.org/10.5603/arm.a2020.0139', 'relation': {}, 'ISSN': ['2543-6031', '2451-4934'], 'issn-type': [{'value': '2543-6031', 'type': 'electronic'}, {'value': '2451-4934', 'type': 'print'}], 'subject': ['Pulmonary and Respiratory Medicine'], 'published': {'date-parts': [[2020, 12, 30]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit